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Abstract
Background: Atherosclerosis is a progressive disease that causes vascular remodeling that can be positive or
negative. The evolution of arterial wall thickening and changes in lumen size under current “standard of care” in
different arterial beds is unclear. The purpose of this study was to examine arterial remodeling and progression/
regression of atherosclerosis in aorta and carotid arteries of individuals at risk for atherosclerosis normalized over a
1-year period.
Methods: In this study, 28 patients underwent at least 2 black-blood in vivo cardiovascular magnetic resonance
(CMR) scans of aorta and carotids over a one-year period (Mean 17.8 ± 7.5 months). Clinical risk profiles for
atherosclerosis and medications were documented and patients were followed by their referring physicians under
current “standard of care” guidelines. Carotid and aortic wall lumen areas were matched across the time-points
from cross-sectional images.
Results: The wall area increased by 8.67%, 10.64%, and 13.24% per year (carotid artery, thoracic aorta and
abdominal aorta respectively, p < 0.001). The lumen area of the abdominal aorta increased by 4.97% per year
(p = 0.002), but the carotid artery and thoracic aorta lumen areas did not change significantly. The use of statin
therapy did not change the rate of increase of wall area of carotid artery, thoracic and abdominal aorta, but
decreased the rate of change of lumen area of carotid artery (-3.08 ± 11.34 vs. 0.19 ± 12.91 p < 0.05).
Conclusions: Results of this study of multiple vascular beds indicated that different vascular locations exhibited
varying progression of atherosclerosis and remodeling as monitored by CMR.
Introduction
Atherosclerosis is a progressive disease that causes vas-
cular remodeling i.e. changes in the vessel wall of
arteries [1]. This remodeling can be positive or negative
[2,3]. Atherosclerosis is a major cause of morbidity and
mortality world-wide with the most serious outcomes
being myocardial infarction, stroke, and death[4,5].
Atherosclerosis affects all vascular beds, including the
coronary, carotid, aorta, and peripheral arteries and is
present years before a cardiovascular event [6]. The evo-
lution of arterial wall thickening and changes in lumen
size i.e., the natural progression/regression of disease
under current “standard of care” in different arterial
beds are unclear.
Recently, black blood cardiovascular magnetic reso-
nance (CMR) has become a useful tool for non-inva-
sively evaluating vascular wall area and lumen area
[7-16]. CMR findings have been extensively validated
against pathology in ex vivo studies of carotid, aorta,
and coronary artery specimens obtained at autopsy and
using experimental models of atherosclerosis [17-19].
Previous studies have examined plaque progression/
regression in carotids, aorta or femoral arteries sepa-
rately but very few studies have examined multiple vas-
cular beds in the same patient population. Furthermore,
a majority of previous studies follow specific lesions in
the artery of interest over time, but do not evaluate
changes in plaque burden over the entire vessel of inter-
est [20,21]. Most previous studies have also examined
relatively advanced atherosclerotic lesions while looking
for progression/regression and effect of treatment
[22,23]. The purpose of this study was to examine
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arterial remodeling and progression/regression of ather-
osclerosis in multiple vascular beds (aorta and carotid
arteries) of individuals at risk for atherosclerosis over
the entire artery of interest and not a specific lesion
(carotids, abdominal aorta, thoracic aorta) normalized
over a one-year period.
Methods
Study population
This study was approved by the local institutional review
board. Informed consent was obtained from all subjects
prior to participation in the study. Three hundred subjects
aged 9 years or older and with at least two risk factors for
atherosclerosis were recruited serially from January 2003 -
December 2006 into an imaging study. Patients were
recruited from the offices of local physicians in the New
York area and at the Mount Sinai Medical Center. The
local physicians screened patients based on their tradi-
tional risk factors for atherosclerosis (age, gender, smoking
status, hypertension, diabetes, lipid profile, and carotid
intima-media thickness measures (IMT)). Any patient who
had at least two risk factors for atherosclerosis (not includ-
ing older age) was recruited into the imaging study. The
following criteria were used to determine a positive risk
factor: A mean IMT > 1.1 mm, or a focal structure that
encroached into the arterial lumen by at least 0.6 mm
represented a positive IMT. A patient was considered to
be hypertensive if either systolic or diastolic blood pres-
sure was greater than 140 and 100 mm HG respectively or
the patient was on antihypertensive medication. A patient
was considered hypercholesterolemic if total cholesterol
was > 200 mg/dl, and LDL was > 160 mg/dl or if the
patient was on a statin. Fasting plasma glucose levels of
more than 126 mg/dl on two or more tests on different
days or HbA1c > 6.5 indicated diabetes.
From this sample of 300 patients who underwent one
or more CMR scans of both aorta and carotid, 28 sub-
jects who underwent CMR of both aorta (thoracic and
abdominal) and carotids (left and right) two or three
times over a two year period were included in this retro-
spective analysis. Study subjects were asked, prior to the
first CMR examination, to complete a detailed health
questionnaire and physical examination (table 1).
Patients needed to have their statin data at the time of
imaging available for inclusion in the retrospective ana-
lysis. Exclusion criteria included: 1) a repeat CMR
within 6 months; 2) age less than 20 years old. All
patients were under the supervision of their respective
primary care physicians and were following current
“standard of care” guidelines.
Three separate vascular beds were analyzed for this
study (carotid arteries, thoracic aorta and abdominal
aorta). Ten subjects had carotid artery images, thoracic
aorta images and abdominal aorta images. Five subjects
had carotid artery images and thoracic images. One sub-
ject had carotid artery images and abdominal aorta
images. Three subjects had thoracic and abdominal aor-
tic images, seven subjects had only carotid images, one
subject had only thoracic aorta images and one subject
had only abdominal aorta images.
The total number of subjects for carotid artery, thor-
acic aorta and abdominal aorta were 23, 19 and 15
respectively.
The duration between first imaging and second ima-
ging or first imaging and third imaging was 17.1 ± 7.6
months (Range 7.6-48.6) in carotids, 17.1 ± 6.7 months
(Range 8.8-30.0) in thoracic aorta and 20.9 ± 7.8 months
(Range 9.3-32.0) for abdominal aorta. In the case of
more than 2 imaging visits, the last visit (furthest inter-
val apart from Visit 1) was chosen as the 2nd visit for
calculating rates of progression/regression.
The percentage of individuals with statin use was
41.7% in carotid artery, 42.1% in thoracic aorta and
40.0% in abdominal aorta. Statin dose was unavailable
from >50% of subjects. High dose statin was used only
in 1 subject in abdominal aorta.
CMR protocol
All MR images were obtained on a 1.5T whole body MR
imaging system (Siemens Sonata, Erlangen, Germany)
that was running Numaris 4.0 operating system. The
system had a maximum gradient amplitude of 40 mT/m
and a slew rate of 200 mT/m/ms. The integrated body
coil was used for transmission. For the carotid images a
custom built 4-channel carotid array was used for signal
reception [13,24] and for the aorta images, a 6 channel
cardiac coil in conjunction with the spine array was
used for signal reception.
Carotid Imaging
Twelve to 24 non-overlapping cross sectional slices cen-
tered on the carotid bifurcation were obtained using the
rapid extended coverage double inversion recovery
turbo spin echo black blood (REX) pulse sequence[25].
Imaging parameters were as follows: proton density
weighted (PDW) non-gated sequence imaging 12 slices
simultaneously (TR/TE = 2130/5.6 ms), with a field of
view of 12 × 12 cm, bandwidth of 488 Hz/pixel, matrix
size of 256 × 256, a turbo factor of 15 and 2 signal
averages. A chemical shift suppression pulse was used to
suppress signal from perivascular fat, not affecting the
signal from intraplaque lipids.
The image slice was 3 mm and the gap between image
slices was 0.3 mm.
Aorta Imaging
Twenty five to 30 transverse images from the origin of
the left subclavian artery to the level of the diaphragm
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were obtained. Some subjects got images of the abdom-
inal aorta using the same method extending from the
level of the diaphragm to the level of the iliac
bifurcation.
The imaging parameters were similar for carotid ima-
ging with the exception of field of view and slice thick-
ness which were 25 cm and 5 mm respectively. The gap
between slices was 0.5 mm. The total examination lasted
60 to 90 minutes.
MR imaging analysis
After MR images were acquired, they were transferred to a
dedicated MR workstation for analysis. An experienced
reader (KH) analyzed all the images. The experienced
observer also qualitatively scored the image quality, using
a scale from 1 to 5, with 5 representing best quality. Sec-
tions with an CMR quality rating of ≤ 2 were excluded
from the analysis [13,19]. The acceptance rate for images
based on these criteria was 72.4% for carotids, 75.6% for
thoracic aorta and 73.4% for abdominal aorta for all
imaging time points. There were similarly no significant
differences between image quality scores between the var-
ious imaging time points. The outer and inner vessel wall
contours were manually traced for the aorta and carotid
artery using a custom software program (VesselMass, Lei-
den University Medical Center, The Netherlands)[26].
Wall area, lumen area, and total vessel area were automa-
tically calculated based on the contours drawn by the soft-
ware program. The normalized wall index (NWI) was
calculated by dividing the wall area by the total vessel area.
Registration of images between the time points was
performed manually by an expert observer using various
fiducial landmarks.
Sample images and the manual tracing of the contours
are shown in Figure 1.
Statistical Analysis
The summary statistics for the data are presented as
mean ± standard deviation (SD). The mean area of the
whole artery is the sum of all areas divided by the
Table 1 Baseline clinical data
Demographics and risk
factors
Carotid (n = 23
Mean ± S.D (Range/dosage or %
if possible)
Thoracic (n = 19
Mean ± S.D (Range/dosage or %
if possible)
Abdominal (n = 15




Age (years) 59.4 ± 10.3 (75-27) 59.8 ± 12.0 (85-35) 63.2 ± 12.3 (85-35) ns
Male sex (%) 66.7 68.4 60.0 ns
Height (m) 1.72 ± 0.08 (1.83-1.55) 1.72 ± 0.10 (1.89-1.55) 1.70 ± 0.09 (1.83-1.55) ns
Weight (kg) 77.5 ± 16.8 (114-52) 78.5 ± 17.1 (123-52) 79.5 ± 16.0 (114-52) ns
Body Mass Index (kg/m2) 26.0 ± 4.9 (39.2-18.9) 26.3 ± 4.0 (34.5-18.9) 27.4 ± 5.0 (39.2-18.9) ns
Hypertension (%) 45.0 38.9 35.7 ns
Diabetes (%) 31.8 26.3 40.0 ns
Smoking status (%)
Active 4.5 11.1 14.3 ns
Quit 45.0 38.9 28.6 ns
Never 49.5 50.0 57.1 ns
History of CAD (%) 27.3 21.1 26.7 ns
Hypercholesterolemia (%) 35.3 29.4 29.4 ns
Statins use (%) 41.7 42.1 40.0 ns
Statins (type)
Atorvastatin 80.0 (5-10) 87.5 (5-10) 100.0 (5-40) ns
Pravastatin 10.0 12.5 0.0 ns
Rosuvastatin 10.0 0.0 0.0 ns
Statins (dosage)
None 60.0 62.5 50.0 ns
Low 40.0 37.5 33.3 ns
High 0.0 0.0 16.7 ns
Total cholesterol (mg/dl) 189.0 ± 52.2 (122-287) 191.3 ± 47.3 (122-287) 186.3 ± 56.2 (122-287) ns
LDL cholesterol (mg/dl) 115.6 ± 42.2 (62-202) 113.0 ± 41.3 (65-202) 106.0 ± 50.8 (62-202) ns
HDL cholesterol (mg/dl) 51.6 ± 15.9 (30-86) 51.3 ± 16.8 (30-86) 55.9 ± 17.6 (32-86) ns
Triglycerides (mg/dl) 110.6 ± 59.7 (46-234) 135.9 ± 86.6 (46-335) 154.4 ± 132.9 (46-500) ns
CAD: Coronary Artery Disease; low dose: atorvastatin 5-10 mg; high dose: atorvastatin 40 mg. Data are mean ± S.D or % a unpaired t-test
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number of slices. All changes (both absolute and per-
centages) are presented as annualized. Statistical analysis
was performed with SPSS (vs 14.0 SPSS Inc., Chicago,
Illinois, USA). Differences between two groups were
evaluated by the unpaired t-test for continuous variables
and by the chi-square test for categorical variables. The
one-sample t-test was used for the comparison of
annual change to zero. For all tests, a p < 0.05 was con-
sidered statistically significant.
Results
In the carotid artery, 23 subjects and 335 slices (right
179 and left 156) were analyzed. For the thoracic
aorta, 19 subjects and 141 slices were analyzed. In the
abdominal aorta, 15 subjects and 106 slices were ana-
lyzed. Sample image analysis tracing of the left carotid
artery showing plaque regression between the two
points on a 56-year-old patient on statin therapy is
shown in Figure 2.
Figure 1 Sample carotid images obtained from a patient (Top panels) and Sample thoracic aorta images (Bottom panels).
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Demographics and Risk Factors
Table 1 provides demographic information, including
the risk factor profile and lipid profile of the study
population subjects among carotid aorta, thoracic aorta,
and abdominal aorta. There were no significant differ-
ences in demographics’ and risk factors among the sub-
jects of carotid artery, thoracic aorta, and abdominal
aorta.
Annual Progression Rate
Tables 2, 3, and 4 demonstrate the annual progression
rate of atherosclerosis and change in lumen size per
year for the carotid artery, thoracic aorta, and abdominal
aorta. For the carotid artery, mean total vessel area
increased by 1.00 mm2/year (2.44%/year, p = 0.004),
mean wall area increased by 1.53 mm2/year (8.67%/year,
p < 0.001) but mean lumen area either remained
unchanged or slightly decreased by -0.53 mm2/year
(-1.23%/year, p = 0.07). For the thoracic aorta, mean
total vessel area increased by 9.19 mm2/year (2.36%/
year, p = 0.009), mean wall area increased by 9.88 mm2/
year (10.64%/year, p < 0.001) but mean lumen area
remained unchanged (-0.69 mm2/year (0.09%/year, p =
ns)). For the abdominal aorta, mean total vessel area
Figure 2 Sample image analysis tracing of the left carotid artery showing plaque regression between the two points on a 56-year-old
patient on statin therapy.
Table 2 Progression rate per year for Carotid artery
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD p*
Means (Data based on all matched locations)
Lumen [mm2] 31.18 ± 8.98 -0.53 ± 4.26 -1.23 ± 12.34 0.07
Wall [mm2] 25.00 ± 9.61 1.53 ± 9.37 8.67 ± 32.54 <0.001
Total Vessel [mm2] 56.17 ± 17.11 1.00 ± 10.72 2.44 ± 15.35 0.004
Normalized Wall Index 0.44 ± 0.06 0.02 ± 0.07 5.11 ± 16.53 <0.001
*One sample t-test vs. 0 for percentage change/year
Table 3 Progression rate per year for thoracic aorta
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD p*
Means (Data based on all matched locations)
Lumen [mm2] 359.10 ± 85.72 -0.69 ± 43.94 0.09 ± 11.98 ns
Wall [mm2] 120.07 ± 39.78 9.88 ± 20.40 10.64 ± 17.97 <0.001
Total Vessel [mm2] 479.17 ± 118.78 9.19 ± 51.72 2.36 ± 110.61 0.009
Normalized Wall Index 0.25 ± 0.04 0.02 ± 0.04 8.23 ± 15.04 <0.001
*One sample t-test vs. 0 for percentage change/year
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increased by 21.26 mm2/year (6.77%/year, p < 0.001),
mean wall area increased by 11.23 mm2/year (13.24%/
year, p < 0.001) and mean lumen area also increased by
10.03 mm2/year (4.97%/year, p = 0.002).
Briefly, the wall area significantly increased for carotid
artery, thoracic aorta, and abdominal aorta. The lumen
area significantly increased for abdominal aorta, but
didn’t change significantly for carotid arteries and thor-
acic aorta. This implies that different vascular locations
may exhibit varying progression of atherosclerosis and
remodeling as monitored by CMR.
Demographics and Risk Factor with and without
statintherapy
Previous studies suggest that use of statin shows regres-
sion of atherosclerotic lesions [27-30]. We therefore
analyzed the demographic information, risk factor, and
lipid profile with and without statin use.
Table 5 shows demographics and risk factors with and
without statin therapy for patients with carotid artery
imaging. There was no significant difference between
patients with and without statin therapy with regard to
other demographics and risk factors including serum
lipid level. Table 6 showed demographic and risk factors
for patients with and without statin therapy for the
thoracic aorta imaging. Regarding gender, everyone on
statin therapy was male (male gender: 100% on statin
therapy vs. 54.5% not on statin therapy, p = 0.04). There
were no significant differences between patients with
and without statin therapy with regard to other factors
including serum lipid levels. Table 7 showed demo-
graphics and risk factors with and without statin therapy
for patients who underwent abdominal aorta imaging.
No significant differences between those with and with-
out statin therapy were observed in demographics and
risk factors.
Annual Progression Rate with and without statin therapy
Table 8 shows annual progression rates comparing
subjects with and without statin therapy for patients
with carotid arteries imaging. Mean lumen area of the
base line was significantly higher in subjects without
Table 4 Progression rate per year for abdominal aorta
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD p*
Means (Data based on all matched locations)
Lumen [mm2] 259.63 ± 85.89 10.03 ± 48.49 4.97 ± 15.86 0.002
Wall [mm2] 103.48 ± 33.72 11.23 ± 15.56 13.24 ± 17.36 <0.001
Total Vessel [mm2] 399.11 ± 112.33 21.26 ± 53.20 6.77 ± 13.85 <0.001
Normalized Wall Index 0.26 ± 0.04 0.01 ± 0.04 6.45 ± 14.87 <0.001
*One sample t-test vs. 0 for percentage change/year
Table 5 Comparison of clinical data for patients with and without statin therapy for Carotid
Demographics and risk factors Mean ± S.D or % Statin(-) (Range or dosage) Statin(+) p
Age (years) 57.0 ± 12.5 (64-27) 62.7 ± 4.9 (72-57) ns
Male sex (%) 64.3 70.0 ns
Height (m) 1.71 ± 0.09 (1.83-1.55) 1.74 ± 0.05 (1.83-1.68) ns
Weight (kg) 72.2 ± 14.6 (90-52) 84.7 ± 17.7 (114-62) ns
Body Mass Index (kg/m2) 24.6 ± 3.6 (28.8-18.9) 28.0 ± 6.0 (39.2-23.4) ns
Hypertension (%) 23.1 60.0 ns
Diabetes (%) 18.2 40.0 ns
Smoking status (%)
Active 7.7 0.0 ns
Quit 38.5 60.0 ns
Never 53.8 40.0 ns
History of CAD (%) 30.8 20.0 ns
Hypercholesterolemia (%) 44.4 25.0 ns
Total cholesterol (mg/dl) 200.4 ± 62.5 (130-287) 176.1 ± 37.6 (128-244) ns
LDL cholesterol (mg/dl) 127.1 ± 49.7 (65-202) 102.6 ± 29.8 (62-147) ns
HDL cholesterol (mg/dl) 54.8 ± 16.4 (33-86) 48.0 ± 15.5 (30-77) ns
Triglycerides (mg/dl) 106.0 ± 60.3 (46-234) 116.4 ± 63.1 (48-233) ns
CAD: Coronary Artery Disease;
Data are mean ± S.D or % a nonpair t-test or c2-test
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Table 6 Comparison of clinical data for patients with and without statin therapy for Thoracic Aorta
Demographics and risk factors Mean ± S.D or % Statin(-) (Range or dosage) Statin(+) p
Age (years) 58.5 ± 10.7 (72-35) 61.6 ± 14.0 (85-35) ns
Male sex (%) 54.5 100.0 0.04
Height (m) 1.68 ± 0.10 (1.83-1.55) 1.77 ± 0.07 (1.89-1.68) 0.06
Weight (kg) 75.5 ± 16.0 (104-52) 82.3 ± 18.7 (123-62) ns
Body Mass Index (kg/m2) 26.5 ± 4.4 (34.5-18.9) 26.1 ± 3.7 (34.2-22.0) ns
Hypertension (%) 30.0 50.0 ns
Diabetes (%) 18.2 37.5 ns
Smoking status (%)
Active 10.0 0.0 ns
Quit 30.0 50.0 ns
Never 50.0 50.0 ns
History of CAD (%) 27.3 12.5 ns
Hypercholesterolemia (%) 44.4 14.5 ns
Total cholesterol (mg/dl) 206.2 ± 57.4 (122-287) 172.1 ± 20.9 (144-205) (0.16)
LDL cholesterol (mg/dl) 127.6 ± 49.2 (65-202) 94.3 ± 17.5 (66-114) (0.11)
HDL cholesterol (mg/dl) 54.0 ± 17.4 (32-86) 47.9 ± 16.6 (30-78) ns
Triglycerides (mg/dl) 136.4 ± 94.3 (46-335) 135.1 ± 82.9 (48-257) ns
CAD: Coronary Artery Disease;
Data are mean ± S.D or % a nonpair t-test or c2-test
Table 7 Comparison of clinical data for patients with and without statin therapy for Abdominal Aorta
Demographics and risk factors Mean ± S.D or % Statin(-) (Range or dosage) Statin(+) p
Age (years) 58.6 ± 12.0 (75-35) 70.2 ± 10.0 (85-60) 0.07
Male sex (%) 55.6 66.7 ns
Height (m) 1.69 ± 0.10 (1.83-1.55) 1.72 ± 0.09 (1.78-1.55) ns
Weight (kg) 76.3 ± 16.7(104-52) 84.3 ± 15.0 (114-74) ns
Body Mass Index (kg/m2) 26.5 ± 4.6 (34.5-18.9) 29.4 ± 6.0 (39.2-24.4) ns
Hypertension (%) 25.0 50.0 ns
Diabetes (%) 22.2 66.7 ns
Smoking status (%)
Active 22.2 0.0 ns
Quit 22.2 40.0 ns
Never 55.6 60.0 ns
History of CAD (%) 33.3 16.7 ns
Hypercholesterolemia (%) 33.3 0.0 ns
Total cholesterol (mg/dl) 188.7 ± 57.9 (122-271) 157.5 ± 21.5 (128-175) ns
LDL cholesterol (mg/dl) 111.0 ± 48.6 (65-195) 74.5 ± 14.7 (62-95) (0.19)
HDL cholesterol (mg/dl) 55.3 ± 21.6 (32-86) 56.8 ± 16.0 (41-78) ns
Triglycerides (mg/dl) 133.1 ± 96.6 (46-335) 184.2 ± 180.7 (48-500) ns
CAD: Coronary Artery Disease;
Data are mean ± S.D or % a non-paired t-test or c2-test
Table 8 Comparison of subjects with and without statin therapy in Carotid area
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD
Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value
Means (data based on all matched locations)
Lumen (mm2) 32.28 ± 7.92 29.73 ± 10.00 <0.01 -0.16 ± 4.59 -1.03 ± 3.77 ns 0.19 ± 12.91 -3.08 ± 11.34 <0.05
Wall (mm2) 25.46 ± 10.01 24.39 ± 9.05 ns 1.35 ± 11.55 1.78 ± 5.33 ns 8.62 ± 38.23 8.72 ± 23.19 ns
Total vessel (mm2) 57.74 ± 16.33 54.12 ± 17.93 ns 1.19 ± 13.63 0.75 ± 4.75 ns 3.16 ± 18.61 1.50 ± 9.52 ns
Normalized wall index 0.43 ± 0.06 0.45 ± 0.06 <0.05 0.01 ± 0.08 0.02 ± 0.06 ns 4.19 ± 17.58 6.30 ± 14.98 ns
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statin than the subjects with statin (32.28 ± 7.92 vs.
29.73 ± 10.00 p < 0.01). The progression rate of lumen
area was significantly elevated in the subjects without
statin therapy than the subjects with statin therapy
(0.19 ± 12.91 vs. -3.08 ± 11.34 p < 0.05). There was no
significant difference in the rate of change of wall area
and total vessel area between the subjects with statin
therapy and without statin therapy.
Table 9 shows the annual progression rate comparison
of subjects with and without statin therapy with thoracic
aorta imaging. Mean lumen area of the baseline was sig-
nificantly higher in the subjects without statin therapy
than the subjects with statin therapy (372.93 ± 84.22 vs.
342.91 ± 85.25 p = 0.03). There were no significant dif-
ferences in the rate of change of lumen area, wall area
and total vessel area between the subjects with statin
and without statin therapy.
Table 10 shows the annual progression rates for sub-
jects with and without statin therapy with abdominal
aorta imaging. Mean lumen area, mean wall area and
total vessel area of the baseline was significantly smaller
in subjects without statin than the subjects with statin
(lumen area: 268.11 ± 72.41 vs. 334.41 ± 89.14 p <
0.001, wall area: 86.39 ± 20.10 vs. 127.56 ± 34.48 p <
0.001, total vessel area: 354.50 ± 87.50 vs. 461.98 ±
114.17 p < 0.001). There were no significant differences
in the rate of change of lumen area, wall area and total
vessel area between the subjects with statin and without
statin therapy.
Discussion
This study demonstrates that in vivo CMR can quantify
changes in atherosclerosis and remodeling simulta-
neously in multiple vascular beds, i.e., the carotid
arteries, thoracic aorta, and abdominal aorta. Results
indicated that different vascular beds have different rates
of progression/regression under current standard of
care.
Previous studies that use CMR have detected changes
of atherosclerotic lumen and wall dimension in carotids.
Saam et al[21] observed 74 subjects having 50-79% ste-
nosis of carotids for 18 months. Results of that study
indicated no significant change of mean total vessel
area, a significant increase of 1.0 ± 2.9 mm2 per year
(p = 0.001) of mean wall area and decrease of 0.6 ± 2.2
mm2 per year (p = 0.02) of mean lumen area. The
results of the current study however showed a non sig-
nificant mean lumen area decrease of 0.53 ± 4.26 mm2
per year. We also observed a decrease in carotid artery
lumen areas indicating progressing atherosclerosis. In
terms of mean total vessel area and mean wall area, our
results were comparable to those obtained by Saam et al
[21]. By contrast, our subjects had a baseline normal
wall index of 0.44 ± 0.06, while the subject’s of Saam
et al showed baseline of normal wall index of 0.63 ±
0.09 indicating that our study population was not as
advanced in atherosclerotic disease stage. A lower nor-
malized wall index has been associated with a signifi-
cantly reduced rate of progression in mean wall area of
carotid artery [21].
Other studies that use CMR have also detected
changes of atherosclerotic lumen and wall dimensions in
subjects treated with lipid-lowering therapy [27-30].
Corti et al. reported an 18% reduction in carotid wall
area, a 5% increase in carotid lumen area and a 15%
reduction in thoracic aorta wall area, 6% increase in
thoracic aorta lumen area in 51 subjects after two years
of treatment with 20 or 80 mg simvastatin. Total vessel
Table 9 Comparison of subjects with and without statin therapy in Thoracic Aortic area
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD
Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value
Means (data based on all matched locations)
Lumen (mm2) 372.93 ± 84.22 342.91 ± 85.25 0.03 2.81 ± 49.89 -4.78 ± 35.71 ns(0.31) 1.58 ± 12.18 -1.66 ± 11.60 ns(0.11)
Wall (mm2) 117.95 ± 29.61 122.55 ± 49.22 ns 10.21 ± 22.42 9.48 ± 17.93 ns 11.14 ± 18.88 10.07 ± 16.96 ns
Total vessel (mm2) 490.89 ± 107.49 465.47 ± 130.27 ns 13.03 ± 60.62 4.70 ± 38.81 ns(0.34) 3.63 ± 11.57 0.86 ± 9.24 ns(0.12)
Normalized wall index 0.24 ± 0.03 0.26 ± 0.04 0.01 0.02 ± 0.03 0.02 ± 0.04 ns 7.13 ± 14.39 9.52 ± 15.79 ns
Table 10 Comparison of subjects with and without statin therapy in Abdominal Aortic area
Baseline ± 1SD Δ/year absolute ± 1SD Δ/year in % ± 1SD
Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value Statin(-) Statin(+) p-value
Means (data based on all matched locations)
Lumen (mm2) 268.11 ± 72.41 334.41 ± 89.14 <0.001 8.59 ± 57.32 12.06 ± 32.77 ns 5.02 ± 18.65 4.89 ± 10.97 ns(0.11)
Wall (mm2) 86.39 ± 20.10 127.56 ± 34.48 <0.001 11.32 ± 16.74 11.11 ± 13.92 ns 15.65 ± 20.23 9.85 ± 11.64 ns
Total vessel (mm2) 354.50 ± 87.50 461.98 ± 114.17 <0.001 19.91 ± 61.96 23.17 ± 38.20 ns 7.18 ± 16.31 6.18 ± 9.50 ns
Normalized wall index 0.25 ± 0.04 0.28 ± 0.05 <0.001 0.02 ± 0.04 0.01 ± 0.02 ns 8.58 ± 17.77 3.45 ± 8.73 ns(0.08)
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area decreased until 12 months of treatment for thoracic
aortic lesions and 18 months for carotid lesions [29,30].
This study showed the regression of atherosclerosis and
changes of vessel remodeling were almost the same
between carotid artery lesions and thoracic aorta lesions.
The baseline of mean carotid artery wall area was 46.5
mm2 (current study: 25.00 mm2), mean lumen area was
32.6 mm2 (current study: 31.18 mm2) and mean thoracic
wall area is 288 mm2 (current study: 120.07 mm2), mean
lumen area is 469.1 mm2 (current study: 359.10 mm2).
Corti et al also showed atherosclerotic plaque regression
with statin therapy. Our study subjects had lower lipids
than the subjects of the study by Corti et al. Therefore
our study showed progression of atherosclerotic lesions
regardless of statin therapy.
Regarding change of the mean lumen area of carotid
arteries and thoracic aorta; our study showed that the
subjects with statin had higher but not significantly dif-
ferent reduction of lumen area than the subjects without
statin. On the contrary, Saam et al. showed the subjects
with statin had significant reduction of mean lumen
area and less regression of mean wall area than the sub-
jects without statin in carotid artery [21]. Different
severity of atherosclerosis in the multiple vascular beds
may cause different changes in wall area and vessel area
with or without statin.
Schoenhagen et al. [31] showed that treatment with
statin was associated with constrictive remodeling in
coronary artery using intravascular ultrasound. The
remodeling ratio was calculated by dividing the lesion
extra elastic membrane area by the reference elastic
membrane area. The plaque area increased 8.9% but the
remodeling ratio decreased 3.0% during 18 month follow
up with atorvastatin 80 mg or pravastatin 40 mg. Statin
therapy may affect vascular constrictive remodeling
without regression of plaque area in carotid artery and
thoracic aorta. Further studies are needed to examine
this phenomenon.
Ayaori et al. [32] reported significant regression of
thoracic aorta mean wall area 12 mm2 but not signifi-
cant change of thoracic aorta mean vessel area and sig-
nificant regression of abdominal aorta mean wall area
11 mm2 and significant enlargement of mean vessel area
8 mm2 in 14 subjects treated with 400 mg bezafibrate
for one year. The regression of atherosclerosis plaque is
similar between thoracic aorta lesions and abdominal
aorta lesions but the change of vessel area is different
between thoracic aorta lesions and abdominal aorta
lesions in subjects treated with 400 mg bezafibrate.
Yonemura et al. [28] reported significant regression of
thoracic aorta mean wall area of 23 mm2, an enlarge-
ment of thoracic aorta vessel area of 15 mm2 and an
insignificant change of abdominal aorta wall area and
vessel area in 19 subjects with 20 mg atorvastatin for
one year. This showed the regression of atherosclerosis
plaque is different between thoracic aorta lesions and
abdominal aorta lesions treated with atorvastatin.
Studies have shown that plaques are more common in
abdominal aorta than in the thoracic aorta [33]. In the
abdominal aorta, fibrous plaques were shown by autopsy
studies to be more common than in the thoracic aorta
and have also been shown to increase in burden with age
[34,35]. The abdominal aorta tapers geometrically and
has higher pressures than the thoracic aorta. It is also
stiffer with less elastin and more collagen[36]. The com-
position of plaque is different between thoracic aorta
lesions and abdominal aorta lesions. Our results showed
a greater reduction in lumen size of the abdominal aorta
than that of thoracic aorta. It is also natural that the for-
mation of aneurysm is more common in abdominal aorta
than in thoracic aorta and carotid artery.
Previous studies have also shown that increased CMR
plaque burden measures are related to previous major
adverse cardiovascular events [37]. This would indicate
that the results of the current study may potentially be
useful in the evaluation of patient risk. The reproduci-
bility of the CMR measures used in this study has been
examined in the past and has been shown to be robust
and reproducible [38].
Limitations
Though this study offers insights into plaque distribu-
tion in various vascular beds, several limitations need to
be noted. First and foremost, this study was a retrospec-
tive analysis performed on a limited sample size. Further
prospective studies in a larger population are needed
before these results can be generalized. Issues that con-
tributed to small sample size were determined primarily
by the logistics of scanning the same individual multiple
times and not by image acquisition issues.
Another limitation of the current study involves analy-
sis of mean values of plaque burden measurements over
the entire artery and not within specific plaques. Specific
plaques may change differently than the entire vessel as
a whole and this could be the reason for some of the
differences between the results obtained in this study
compared to previous work. Significant differences can
be observed earlier if only specific lesions are chosen for
analysis as compared to the whole vessel segment.
Finally, plaque characterization analysis was not per-
formed. As a result, the effect of the presence or
absence of calcification, intra plaque hemorrhage, and/
or lipid rich necrotic cores on plaque progression could
not be assessed. One of the reasons for the lack of pla-
que characterization was due to the fact that the
patients in this study were at an earlier stage of athero-
sclerosis compared to previous studies that examined
advanced disease.
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Other limitations include that fact that annualized
rates of progression/regression were determined using a
linear model. The rates of progression and regression in
individuals might vary with the age and extent of disease
and need not be linear. The results of this study cannot
therefore be extrapolated to determine progression/
regression for a general population. Yet another limita-
tion of this study is the fact that a regression analysis
was not performed. The current analysis approach was
chosen to mimic the approach by Saam et al [21,23] in
order to allow for direct comparison of our data with
previously published work. A multivariate regression
model will provide better insights with regard to inde-
pendent predictors for plaque progression. These will
the basis of future work in a prospective study in a lar-
ger population.
Conclusion
Firstly, this study demonstrates the utility of non-inva-
sive CMR for quantifying simultaneously, changes in
atherosclerotic plaques and vessel lumen size in multiple
vascular beds i.e., carotid artery, thoracic aorta, and
abdominal aorta. The atherosclerotic plaques progress
with time (over an 18 month period) in carotid artery,
thoracic aorta, and abdominal aorta. In our patient
population, the lumen size increased in the abdominal
aorta but did not change in carotid artery and thoracic
aorta. Thus, different vascular locations exhibited vary-
ing progression/regression of atherosclerosis and remo-
deling. Furthermore, the fact that this study shows a
lack of correlation between the change in lumen and
wall areas confirms that measurement of lumen stenosis
provides an incomplete picture of atherosclerosis pro-
gression and regression in any vascular bed in any sub-
ject regardless of the stage of atherosclerosis.
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